Cargando…
Is arginase a potential drug target in tobacco-induced pulmonary endothelial dysfunction?
BACKGROUND: Tobacco-induced pulmonary vascular disease is partly driven by endothelial dysfunction. The bioavailability of the potent vasodilator nitric oxide (NO) depends on competition between NO synthase-3 (NOS3) and arginases for their common substrate (L-arginine). We tested the hypothesis wher...
Autores principales: | Henno, Priscilla, Maurey, Christelle, Le Pimpec-Barthes, Françoise, Devillier, Philippe, Delclaux, Christophe, Israël-Biet, Dominique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391310/ https://www.ncbi.nlm.nih.gov/pubmed/25889611 http://dx.doi.org/10.1186/s12931-015-0196-4 |
Ejemplares similares
-
In smokers, Sonic hedgehog modulates pulmonary endothelial function through vascular endothelial growth factor
por: Henno, Priscilla, et al.
Publicado: (2017) -
Interstitial Lung Disease-Complicated Anti-MDA5 Antibody in Clinically Amyopathic Dermatomyositis Patients: Report of Two Cases With Distinct Clinical Features
por: Pacot, Laurence, et al.
Publicado: (2020) -
Arginase Inhibitor in the Pharmacological Correction of Endothelial Dysfunction
por: Pokrovskiy, Mihail V., et al.
Publicado: (2011) -
Development of Novel Arginase Inhibitors for Therapy of Endothelial Dysfunction
por: Steppan, Jochen, et al.
Publicado: (2013) -
ARGINASE PROMOTES ENDOTHELIAL DYSFUNCTION AND HYPERTENSION IN OBESE RATS
por: Johnson, Fruzsina K., et al.
Publicado: (2014)